Journal of Andrology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published-Ahead-of-Print June 20, 2008, DOI:10.2164/jandrol.108.005454

This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
29/5/534    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Basaria, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Basaria, S.

Androgen Deprivation Therapy, Insulin Resistance and Cardiovascular Mortality: An Inconvenient Truth

Shehzad Basaria *

* To whom correspondence should be addressed. E-mail: sbasari1{at}jhmi.edu.

Prostate cancer (PCa) is the most common cancer in men. Androgen-deprivation therapy (ADT) is used in the treatment of locally advanced and metastatic PCa. Although its use as an adjuvant therapy has resulted in improved survival in some patients, ADT has negative consequences. Complications like osteoporosis, sexual dysfunction, gynecomastia, and adverse body composition are well-known. Recent studies have also found metabolic complications in these men. Studies show that short-term ADT (3-6 months) results in development of hyperinsulinemia without causing hyperglycemia. Studies of men undergoing long-term (≥ 12 months) ADT reveal higher prevalence of diabetes and metabolic syndrome compared to controls. In addition, men undergoing ADT also experience higher cardiovascular mortality. Long-term prospective studies of ADT are needed to determine the timing of onset of these complications and to employ strategies to prevent them. In the meantime, baseline and serial screening for fasting glucose and other cardiac risk factors in men receiving ADT is prudent. In selected cases, glucose tolerance test and cardiac evaluation may be required.


Key words: Prostate • Androgen Deprivation • Cardiovascular mortality • Insulin Resistance • Metabolic Syndrome






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by The American Society of Andrology.